Please assess the completion status of the following clinical trial:

Trial Title: Thyroid Hormones Homeostasis and Energy Metabolism Changes During Stimulation of Endogenously Secreted Bile Acids (BAs)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Age greater than or equal to18 years, male or female~Written informed consent~EXCLUSION CRITERIA:~Hypo- or hyperthyroidism (history or serum thyroid-stimulating hormone (TSH) greater than 5.0 or less than 0.4 miU/L)~Blood pressure greater than 140/90 mmHg (26) or receiving antihypertensive therapy~History of cardiovascular disease~BMI less than or equal to 20 or greater than or equal to 27 Kg/m(2)~Diabetes mellitus (fasting serum glucose greater than or equal to 126 mg/dL)~Hyperlipidemia (serum total cholesterol greater than or equal to 240 mg/dL, triglycerides greater than or equal to 220 mg/dL, and/or use of antilipemic therapy)~Liver disease or ALT serum concentrations greater than 1.5 times the upper laboratory reference limit~Hyperbilirubinemia (serum total bilirubin greater than 1.5 mg/dL)~Renal insufficiency or estimated creatinine clearance less than or equal to 50 mL/min (MDRD equation)~Anemia (Hemoglobin concentration less than or equal to 11.1 g/dL females, and 12.7 g/dL males)~History of cholecystectomy or cholelithiasis (by ultrasound at screening).~History of malabsorption, or food allergies/intolerances that would preclude participant from consuming foods required for study~Claustrophobia~History of illicit drug or alcohol abuse within the last 5 years; current use of illicit drugs (by history) or alcohol (CAGE greater than 3)~Psychiatric conditions or behavior that would be incompatible with safe and successful participation in this study~Current use of medications/dietary supplements/alternative therapies known to alter thyroid function, energy expenditure or bile acid secretion~History of weight loss or weight gain of greater than 3 percent body weight over the past 2 months (self-reported)~Pregnancy/breastfeeding/hormonal contraceptive use and childbirth within the last 6 months~Perimenopausal (as self-described within two years from onset of amenorrhea or current complaints of hot flashes)~Current smoker

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1: Carb meal, fat meal, sincalide, placebo, urso (Type: EXPERIMENTAL): Participants randomized to consume a 100% carbohydrate meal day 1, then a high fat (72% fat, 8% protein, 20% carbohydrate) meal day 2, IV sincalide 0.04mcg/kg + PO placebo day 3, IV placebo + PO placebo day 4, and IV placebo + PO Ursodiol 15mg/kg day 5
- 2: Fat meal, carb meal, sincalide, placebo, urso (Type: EXPERIMENTAL): Participants randomized to consume a high fat (72% fat, 8% protein, 20% carbohydrate) meal day 1, then a 100% carbohydrate meal day 2, IV sincalide 0.04mcg/kg + PO placebo day 3, IV placebo + PO placebo day 4, then IV placebo + PO Ursodiol 15mg/kg day 5
- 3: Carb meal, fat meal, placebo, sincalide, urso (Type: EXPERIMENTAL): Participants randomized to consume a 100% carbohydrate meal day 1, then a high fat (72% fat, 8% protein, 20% carbohydrate) meal day 2, IV placebo + PO placebo day 3, IV sincalide 0.04mcg/kg + PO placebo day 4, then IV placebo + PO Ursodiol 15mg/kg day 5
- 4: Fat meal, carb meal, placebo, sincalide, urso (Type: EXPERIMENTAL): Participants randomized to consume a high fat (72% fat, 8% protein, 20% carbohydrate) meal day 1, then a 100% carbohydrate meal day 2, IV placebo + PO placebo day 3, IV sincalide 0.04mcg/kg + PO placebo day 4, the IV placebo + PO Ursodiol 15mg/kg day 5

Based on this trial design, predict the completion outcome and termination type (if applicable).